08-12-2011: Cellzome announced that Dr. Gitte Neubauer, one of the scientific founders of Cellzome, has received the highly esteemed EU Women Innovators Award. The award recognizes her outstanding contribution in translating academic research into a commercial venture through the foundation of Cellzome. The prize value of €100,000 awarded by the European Commission Innovation Union, was presented to Dr. Neubauer by the president of the European Commission, José Manuel Barroso in a ceremony as part of the Innovation Convention 2011 in Brussels.
Dr. Neubauer founded Cellzome together with a team of scientists and biotech veterans as a spin-out of the European Molecular Biology Laboratory in Heidelberg in 2000. She applied her experience and know-how in proteomics to build Cellzome’s leading proteomics technology platform. More recently, she started the chemoproteomics-based assay development and screening group, to allow the efficient application of the technology to drug discovery. Today, Cellzome employs about 100 scientists and it applies its Kinobeads™ and Episphere™ technologies to the discovery of novel drug candidates to treat inflammatory diseases and cancer.
Receiving the award, Dr. Neubauer said: “I am very honoured to receive such a prestigious award and would like to thank the whole team of Cellzomers who have made the company so successful. It has been extremely rewarding to work with so many talented people over the years. I hope that the award is going to encourage more women to translate their research into innovation.”
Cellzome announced that Dr. Gitte Neubauer, one of the scientific founders of Cellzome, has received the highly esteemed EU Women Innovators Award. The award recognizes her outstanding contribution in translating academic research into a commercial venture through the foundation of Cellzome ... more
Cellzome announced the award of a grant by the UK government-backed Technology Strategy Board under its Regenerative Medicine Programme: “Tools and Technologies” for a project which will address the need for better characterisation of human stem cells. Cellzome will use its EpisphereTM te ... more
A study published in Nature by Cellzome and others has identified that a small molecule inhibitor of BET proteins could potentially be used to treat the aggressive and often incurable mixed lineage (MLL-fusion) leukaemia.The molecular association between BET proteins and factors involved in ... more
Biofrontera was informed by the European Commission that its product Ameluz® (in development called BF-200 ALA) was approved for distribution throughout the entire EU, Norway, Island and Liechtenstein. Already in October had the responsible "European Medicines Agency" recommended the approv ... more
Takeda Pharmaceutical Company Limited announced that the European Commission has granted marketing authorisation for Edarbi® (azilsartan medoxomil), a new once-daily angiotensin receptor blocker (ARB) (also known as angiotensin II receptor antagonist [AIIRA]) for the treatment of essential ... more
Cellzome announced that Dr. Gitte Neubauer, one of the scientific founders of Cellzome, has received the highly esteemed EU Women Innovators Award. The award recognizes her outstanding contribution in translating academic research into a commercial venture through the foundation of Cellzome ... more